Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on creating novel precision medicines for the treatment of rare muscle disorders. Our intimate knowledge of integrated muscle physiology at a whole-body level allows us to develop innovative solutions for patients with muscle disease where significant unmet medical need exists. By protecting and improving muscle health, our goal is to dramatically enhance the lives of people living with progressive muscle disorders.
Moving Muscle Health Forward
The path to effective therapies starts with the patient. People living with rare muscle disorders don’t let the disease define them. At Edgewise, our goal is to develop innovative therapies for progressive muscle disorders, with the same boldness and courage of the patients and families.
Protecting Muscles
Powered by our proprietary drug discovery platform, Edgewise Therapeutics is leading the development of a novel and holistic therapeutic approach to protect muscle. We directly target the muscle fibers of patients with rare muscle disorders with the aim of protecting the muscle from progressive damage. Our goal is to create healthier muscle and ultimately enhanced physical function. We are advancing our lead candidate in clinical development, with an initial focus on Duchenne, Becker and Limb-girdle muscular dystrophies, and McArdle disease.
Transforming Muscle Research
We know that for patients with rare muscle disorders, every day without an effective treatment is a day too late. We are driven by this urgency to develop novel precision medicines for severe and rare disorders.
Our Values
connection
excellence
courage
Latest News
Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9
August, 03 2022
View MoreEdgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9
August, 03 2022
Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)
July, 12 2022
View MoreEdgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)
July, 12 2022